Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LLY

LLY - Eli Lilly & Co Stock Price, Fair Value and News

$1023.75-15.76 (-1.52%)
Market Closed

62/100

LLY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

62/100

LLY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1066.42

Target 3M

$1064.29

Target 6M

$1065.35

LLY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LLY Price Action

Last 7 days

-5.1%

Last 30 days

-5.1%

Last 90 days

21.2%

Trailing 12 Months

27.2%

LLY RSI Chart

LLY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LLY Valuation

Market Cap

967.8B

Price/Earnings (Trailing)

52.57

Price/Sales (Trailing)

16.29

EV/EBITDA

40.94

Price/Free Cashflow

60.26

LLY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1066.42

Target 3M

$1064.29

Target 6M

$1065.35

LLY Fundamentals

LLY Revenue

Revenue (TTM)

59.4B

Rev. Growth (Yr)

53.87%

Rev. Growth (Qtr)

13.13%

LLY Earnings

Earnings (TTM)

18.4B

Earnings Growth (Yr)

475.34%

Earnings Growth (Qtr)

-1.38%

LLY Profitability

EBT Margin

37.87%

Return on Equity

77.38%

Return on Assets

16.02%

Free Cashflow Yield

1.66%

LLY Investor Care

Dividend Yield

0.57%

Dividend/Share (TTM)

5.8

Buy Backs (1Y)

0.41%

Diluted EPS (TTM)

20.44

LLY Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202549.0B53.3B59.4B0
202435.9B38.9B40.9B45.0B
202327.7B29.5B32.1B34.1B
202229.3B29.1B29.2B28.5B
202125.5B26.7B27.8B28.3B
202023.1B22.9B23.2B24.5B
201921.6B21.7B21.8B22.3B
201820.4B20.9B21.3B21.5B
201720.9B20.6B20.3B20.0B
201620.2B20.6B20.8B21.2B
201519.6B19.6B19.7B20.0B
201422.2B21.2B20.3B19.6B
201322.6B22.9B23.3B23.1B
201224.0B23.4B22.7B22.6B
201123.4B23.9B24.4B24.3B
201000023.1B
Get all data in R, Python etc through our Historical Stock Data APIs

About Eli Lilly & Co

LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
 CEO
 WEBSITElilly.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers General
 EMPLOYEES39000

Eli Lilly & Co Frequently Asked Questions

LLY is the stock ticker symbol of Eli Lilly & Co. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Eli Lilly & Co is 967.84 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check LLY's fair value in chart for subscribers.

The fair value guage provides a quick view whether LLY is over valued or under valued. Whether Eli Lilly & Co is cheap or expensive depends on the assumptions which impact Eli Lilly & Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LLY.

As of Wed Jan 28 2026, LLY's PE ratio (Price to Earnings) is 52.57 and Price to Sales (PS) ratio is 16.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LLY PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Eli Lilly & Co has provided 0.292 (multiply by 100 for percentage) rate of return.